Millions of people worldwide are losing their sight waiting for corneal transplants. To end this dependence on donors, researchers are working on 3D-printing replacement corneas from stem cells.
A new multimillion-euro international research network has been set up to accelerate this — and the wider revolution in regenerative medicine that is reshaping what modern healthcare can do.
The human body cannot repair a damaged cornea. It cannot regenerate a failing liver, rebuild destroyed cartilage, or replace tissues lost to disease and injury.
For centuries, that was the boundary of medicine. Regenerative medicine is dedicated to innovations that dismantle that boundary.
Crowdhelix , a global open innovation platform connecting researchers, industry leaders and policymakers has launched the Regenerative Medicine Helix, an international open innovation network uniting 110 leading experts across 68 organisations in 24 countries, dedicated to turning the science of tissue regeneration into accessible, real-world therapies.
Growing corneas in the lab
The Helix is launching alongside its flagship project, KeratOPrinter — a Horizon Europe-funded initiative developing the world’s first dedicated 4D bioprinting suite for full-thickness human corneas.
Using hypoimmune iPSC-derived stem cells, advanced clinical-grade bioinks, novel corneal holder technology, and AI-driven quality control, KeratOPrinter aims to produce fully functional, biocompatible corneas that can be transplanted into patients — no donor required.
The scale of the problem it addresses is striking. Corneal disease is one of the leading causes of blindness globally, yet donor corneas remain critically scarce, particularly in lower-income countries where the vast majority of affected patients live.
“The goal of KeratOPrinter is simple to state and very challenging to achieve: to give millions of people back their sight,” said Prof. Heli Skottman , KeratOPrinter Project Coordinator at Tampere University, Finland.
“We are developing a bioprinting suite that produces native-like human corneas with the precision, safety and reproducibility needed for clinical use — entirely independent of donor availability. This is what a solution to corneal blindness looks like”.
“The Regenerative Medicine Helix connects us with researchers, clinicians, industry partners and regulators across Europe who are all working toward the same goal. That kind of community accelerates everything”.
Next frontier in medicine
Beyond corneal repair, regenerative medicine is advancing on multiple fronts simultaneously — bioprinted liver tissue for transplantation, stem cell therapies for conditions that remain untreatable by conventional means, and tissue engineering approaches that could one day make donor waiting lists a thing of the past.
The Regenerative Medicine Helix exists to serve the entire ecosystem driving this forward: researchers, healthcare professionals, biotech and MedTech companies, regulators, policymakers, and investors — all connected through a single, active collaboration network focused on translating science into impact.
“Regenerative medicine has the potential to fundamentally change what healthcare can offer patients,” said Evangelos Koulis , Regenerative Medicine Helix Manager at Crowdhelix.
“The Helix exists to remove the barriers between discovery and patient benefit: connecting expertise, aligning regulatory strategies, and building the partnerships that move this science from the laboratory to the clinic.
“KeratOPrinter is an outstanding example of what this field can achieve with the right team, the right funding, and the right collaborative infrastructure behind it.”
To join the Regenerative Medicine Helix or learn more about KeratOPrinter, visit keratoprinter-project.eu and crowdhelix.com.
